Refractory Cutaneous T Cell Lymphoma Therapeutics
1. Istodax patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US4977138 | BRISTOL-MYERS | FR901228 substance and preparation thereof |
Aug, 2013
(12 years ago) | |
| US7611724 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| US7608280 | BRISTOL-MYERS | Method of producing FR901228 |
Aug, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2014 |
| Orphan Drug Exclusivity(ODE) | Jun 16, 2018 |
| Orphan Drug Exclusivity(ODE-12) | Jun 16, 2018 |
Drugs and Companies using ROMIDEPSIN ingredient
NCE-1 date: 05 November, 2013
Market Authorisation Date: 05 November, 2009
Dosage: POWDER
How can I launch a generic of ISTODAX before it's drug patent expiration?
More Information on Dosage
ISTODAX family patents
2. Targretin patent expiration
Treatment: Topical treatment of cutaneous lesions in patients with cutaneous t-cell lymphoma (stage ia and ib) who have refractory or persistent disease after other therapies or who have not tolerated other ther...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5780676 | BAUSCH | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
Jul, 2015
(10 years ago) | |
| US5962731 | BAUSCH | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
Oct, 2016
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-164) | Jul 29, 2018 |
Drugs and Companies using BEXAROTENE ingredient
Market Authorisation Date: 29 December, 1999
Dosage: CAPSULE; GEL
More Information on Dosage
TARGRETIN family patents